亚盛医药-B:细胞凋亡赛道领军者 加速迈向全球化

东吴证券
Jan 27

投资要点研发管线独具特色,赴美上市开启国际化新篇章:亚盛医药致力于血液瘤小分子药物开发,管线专注细胞凋亡和激酶抑制剂。其中,耐立克已在国内获批上市,海外权益授权武田,开启重磅全球合作。另一款核心产品APG-2575 已在国内递交上市申请,海外III 期临床推进中。1 月24日挂牌纳斯达克,赴美上市开启国际化新篇章。耐立克商业化有望加速增长,重磅合作凸显海外价值:耐立克是国产首个获批的三代BCR-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10